An experimental pill from Axsome Therapeutics had a rapid and significant effect on major depression in pivotal study, the company said Monday, evidence that will support an application for Food and Drug Administration approval.
The treatment, AXS-05, met its goals in a 327-patient trial, outperforming placebo on a measure of depression after one week and sustaining the effect for another five.
About the Author Reprints
